Non-alcoholic fatty liver disease (NAFLD) is not only a consequence of insulin resistance,
but it is also an important cause of insulin resistance and major non-communicable diseases …

The concept of metabolic health, particularly in obesity, has attracted a lot of attention in the
scientific community, and is being increasingly used to determine the risk of cardiovascular …

Type 2 diabetes mellitus (T2DM) is characterized by tissue-specific insulin resistance and
pancreatic β-cell dysfunction, which result from the interplay of local abnormalities within …

Body fat distribution is a major, heritable risk factor for cardiometabolic disease, independent
of overall adiposity. Using exome-sequencing in 618,375 individuals (including 160,058 non …

Incretin receptor agonists have revolutionized the treatment of obesity, achieving up to 15–
25% weight loss in many patients, ie, at a rate approaching that achieved with bariatric …

Non‐alcoholic fatty liver disease (NAFLD) is a disorder characterized by excessive
accumulation of fat in the liver that can progress to liver inflammation (non‐alcoholic …

Sarcopenia, a condition of low muscle mass, quality, and strength, is commonly found in
patients with chronic liver disease (CLD) and is associated with adverse clinical outcomes …

Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide, affected by
both genetics and environment. Type 2 diabetes (T2D) stands as an independent …

Tissue-to-tissue crosstalk regulates organ function, according to growing data. This
phenomenon is relevant for pancreatic β-cells and the liver, as both tissues are involved in …

Introduction and aim Myostatin and follistatin are the main hormones for regulating muscle
mass, and previous research suggests they are modulated by resistance training. We …